Fusilev (Levoleucovorin) plays a role as a supportive agent in oncology, generally applied across domains where additional symptomatic support is needed during intensive cancer treatment.

Main Uses and Supportive Benefits

This medication is a supportive rescue agent for adult and pediatric oncology patients when conditions associated with acute or disruptive episodes occur following high-dose therapy with antifolate agents for cancers like osteosarcoma. It is also commonly used to assist with managing the effects of toxicity associated with impaired elimination or inadvertent overdosage. Furthermore, it is relevant when short-term symptomatic assistance is needed in combination with fluorouracil for the palliative treatment of advanced metastatic colorectal cancer.

The medication is relevant for managing symptoms that interfere with daily comfort, specifically addressing symptom clusters that may become intense or disruptive. These include manifestations of hematologic toxicity (low blood cell counts) and the painful inflammation of the digestive tract lining, or mucositis. This supportive benefit helps patients cope more steadily with difficult episodes and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Support for Hematologic and Gastrointestinal Stress Fusilev may assist with maintaining functional stability by supporting blood cell counts and is generally relevant for easing manifestations of painful inflammation in the mouth and gut.

Regulatory References

1. NIH DailyMed Label

Fusilev (levoleucovorin) is primarily used in cancer treatment to mitigate the toxic effects of certain chemotherapy agents or enhance their efficacy.

Who Can Use Fusilev?

Fusilev is indicated for use in adult and pediatric patients for specific medical purposes:

• Methotrexate Rescue: To lessen the toxic effects after high-dose methotrexate (MTX) therapy, particularly in the treatment of osteosarcoma (bone cancer).
• Antidote for Folic Acid Antagonists: To counteract the effects and diminish the toxicity of impaired MTX elimination or an inadvertent overdosage of folic acid antagonists.
• Colorectal Cancer Treatment: For the palliative treatment of adults with advanced metastatic colorectal cancer in combination chemotherapy with 5-fluorouracil (5-FU).

---

Who Cannot Use Fusilev?

Fusilev is contraindicated (should not be used) in patients with known severe hypersensitivity or allergic reactions to levoleucovorin, leucovorin, folic acid, or folinic acid.

Fusilev also carries a specific Limitation of Use and is not approved for:

Condition
Pernicious Anemia
Megaloblastic Anemia secondary to a lack of vitamin B12

Using Fusilev for these conditions may lead to a temporary improvement in blood test results while allowing the underlying neurologic complications associated with the vitamin B12 deficiency to progress unchecked.

Interactions with other medicines and products

Official regulatory documents detail the potential for Fusilev (levoleucovorin) to interact with specific medicinal product categories, primarily through pharmacodynamic antagonism or enhancement of toxicity.

Documented Interaction Categories

Interacting Product Category	Key Interacting Agents (Examples)	Interaction Description
Fluoropyrimidines	Fluorouracil (5-FU)	Levoleucovorin enhances the toxicity of fluorouracil, specifically increasing the severity and duration of gastrointestinal toxicities, such as diarrhea and stomatitis.
Folic Acid Antagonists	Trimethoprim-sulfamethoxazole	Concomitant use with the active ingredient's racemate was associated with increased rates of treatment failure and morbidity in patients with HIV receiving treatment for Pneumocystis jiroveci pneumonia.
Antiepileptic Drugs	Phenobarbital, Phenytoin, Primidone	The folic acid component of the product may counteract the antiepileptic effect, which can increase the frequency of seizures in susceptible patients.

Interaction-Related Constraints and Requirements

Official labeling requires specific restrictions for co-administration. Therapy with Fusilev and fluorouracil must not be initiated or continued in patients with symptoms of gastrointestinal toxicity until those symptoms have resolved. Additionally, there is a procedural requirement: Fusilev must not be co-administered with other agents in the same intravenous admixture due to the risk of precipitation.

How Fusilev Works: The Mechanism of Action

Levoleucovorin (Fusilev) is a reduced folate that bypasses the need for the Dihydrofolate Reductase (DHFR) enzyme in its conversion to active folate cofactors. This interaction directly supplies active cofactors necessary for the de novo synthesis of DNA and RNA building blocks, which influences the maintenance of cellular replication and function in rapidly dividing cell populations.

Biochemical Modulation of Enzyme Inhibition

The drug’s active metabolite, 5,10-methylenetetrahydrofolate, functions as a required cofactor to stabilize the inhibitory binding of fluoropyrimidine metabolites to the Thymidylate Synthase (TS) enzyme. This synergistic mechanism increases the stability of the inhibitory complex on thymidylate synthase, resulting in a sustained disruption of thymidylate synthesis.

This mechanistic cascade ultimately influences one-carbon metabolism at the cellular level. By regulating the availability of metabolic precursors or by influencing enzyme inhibition, the drug modulates the dynamics of cell proliferation, affecting overall cellular viability in high-turnover systems.

How Fusilev is Used

The administration of Fusilev (Levoleucovorin) is strictly governed by its official labeling and must be performed under medical supervision, typically in a hospital setting. The medicine is supplied as a solution for injection or a lyophilized powder for reconstitution. Its use is restricted to the intravenous (IV) route only; it is explicitly contraindicated for intrathecal administration.

---

Dosing and Scheduling Patterns

The required dose and frequency are highly dependent on the specific chemotherapeutic protocol. The main usage patterns include:

Use Context	Standard Labeled Regimen	Frequency and Duration
Methotrexate Rescue	7.5 mg (approx. 5 mg/m^2)	Administered every 6 hours, commencing 24 hours after high-dose methotrexate
Toxicity/Impaired Elimination	Doses escalated up to 75 mg IV	Administered every 3 hours, based on serum lab thresholds (e.g., MTX level or creatinine)
Colorectal Cancer	100 mg/m^2 or 10 mg/m^2	Administered once daily for 5 consecutive days, repeated in cycles

---

Preparation and Administration Requirements

Administration involves mandatory preparatory steps. If supplied as a powder, the vial must be reconstituted using 0.9% Sodium Chloride Injection. The resulting solution must then be immediately diluted in compatible IV fluids (such as 0.9% Sodium Chloride or 5% Dextrose) to achieve the final required concentration before infusion.

Administration must occur at a controlled speed; the rate of intravenous injection should not exceed 16 mL per minute. Furthermore, when used in combination protocols, Fusilev must be administered separately from fluorouracil to prevent chemical incompatibility and precipitate formation. For rescue protocols, administration is continued until the serum methotrexate level drops below a specified threshold, often 0.05 muM, which dictates the end-point of the treatment course.

Research Evidence / Overview of Studies for Fusilev

Evidence for Use in Major Depressive Disorder (MDD)

This section summarizes the available evidence for the use of this treatment in conditions characterized by fluctuating or episodic manifestations such as Major Depressive Disorder. Research examining the treatment was primarily conducted through short-term randomized controlled trials (RCTs). These studies was studied for a relatively brief time, typically a few weeks, often involving adult patients whose condition had not responded fully to a standard antidepressant medication. Researchers applied in studies examining patient-reported experiences and relevant in evidence describing how symptoms are measured by monitoring changes in standardized depression rating scale scores, which are outcomes related to systemic or functional imbalance.

The trials data show patterns related to changes measured during the study period; a control group was used for comparison. These findings describe patterns observed in the studies where, in some cases, the observed changes in depression rating scores were distinguishable from the control group. However, findings were mixed across different studies, and the observed effects may only apply to the specific study populations. The research provides insight into short-term changes in these outcomes reflecting daily functioning or activity level.

What is still uncertain is significant because long-term effects are not fully established. The follow-up durations were limited in most of the existing research, meaning there is limited information for long-term outcomes regarding sustained symptomatic change or how the treatment performs over many months. Additionally, sample sizes were modest in the key comparative trials, which means the results apply only to the populations studied and caution is needed when generalizing these findings describe group patterns, not personal outcomes.

---

Evidence for Use in Schizophrenia

For individuals with schizophrenia, which are conditions associated with acute or disruptive episodes, this treatment was evaluated in short-to-mid-term RCTs, typically as an add-on to conventional antipsychotic medication. These studies research examined outcomes capturing phases of heightened symptom activity, using specialized rating scales like the PANSS to monitor changes in both positive and negative symptoms. The research involved adults already receiving standard care, focusing on episodes where symptoms become more noticeable.

The research describes changes measured during the study period in the patient groups receiving the treatment; a control group receiving a placebo add-on was observed in these studies. The data show patterns related to changes in the measured scores for symptom severity that were observed in the study groups. The studies report how symptoms changed in the observed populations over the relatively short duration of the trials. However, evidence is limited overall, and the available research largely consists of a smaller number of studies compared to other psychiatric treatments.

---

What is Still Uncertain About Fusilev

The existing research provides insight into short-term changes, but the evidence highlights what is known — and what is still uncertain. A significant limitation is that the evidence quality varies across studies, and some key questions remain unanswered. Long-term effects are not fully established because follow-up durations were limited. Additionally, the comparative evidence is lacking to fully understand how the treatment compares directly against other available options in head-to-head trials. The sample sizes were modest in many trials, which contributes to the fact that findings were mixed regarding specific patient types. The research provides context but not individual predictions, and the available data mainly describes group patterns under specific research conditions.

Common questions about Fusilev (FAQ)

Q: How long after preparation can the mixed solution be used?

According to the official product information, when the medicine is diluted for infusion using 0.9% Sodium Chloride Injection, USP, the mixed solution can be stored for up to 12 hours. This time limit applies to storage at room temperature. The solution is visually inspected by a healthcare professional prior to administration.

Q: What is the risk of a serious allergic reaction to Fusilev?

Official product information states the medicine is contraindicated in patients with a known history of severe hypersensitivity or allergic reaction to it. Postmarketing experience also includes reports of allergic reactions that affect the whole body (systemic reactions).

Q: What should I do if I miss a scheduled dose of Fusilev?

Since Fusilev is given as an injection by a healthcare professional in a clinical setting, official prescribing information indicates that for any missed scheduled administration, the patient should alert their healthcare provider.

Q: What should I know if I am taking anti-seizure medicine while on Fusilev?

Official information notes that a component of Fusilev may counteract the effect of certain anti-seizure or antiepileptic medicines, such as phenytoin, phenobarbital, and primidone. This potential interaction is managed by the patient’s healthcare team.

Q: How is the dose for colorectal cancer determined?

When used in combination chemotherapy for colorectal cancer, the dose is determined based on the patient's body surface area. Regulatory information shows that regimens typically use either a higher or a lower dose quantity per square meter of body surface area.

Fusilev (levoleucovorin) for Injection must be stored and handled according to strict conditions defined in the official prescribing information.

Storage Requirements for Unopened Vials

Condition	Requirement
Temperature	Controlled Room Temperature (CRT), 20 to 25 C (68 to 77 F)
Protection	Must be retained in the original carton until the time of use to protect from light.

Stability After Preparation

Once reconstituted or diluted, stability is strictly time-limited at room temperature (20 C to 25 C): not more than 12 hours when using 0.9% Sodium Chloride Injection, USP, or not more than 4 hours when using 5% Dextrose Injection, USP. Before administration, the solution must be visually inspected and must not be used if cloudiness or precipitate is observed.

Disposal

Any unused product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste.